This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dumbest of This Week's 5 Dumbest: KV Pharmaceutical Goes Price Hiking

NEW YORK ( TheStreet) -- KV Pharmaceutical's (KV.A) arbitrary and blatantly greedy pricing strategy was considered the dumbest thing on Wall Street this week by readers of TheStreet.

As of late Friday, about 65% of the roughly 175 readers that took our poll thought that KV's decision to hike the price of its new prenatal drug was a particularly bad idea.

The company recently won the exclusive rights to produce a shot that helps prevent premature births. However, the shot that once cost about $10 will now cost $1,500.

"All the upfront development of the drug was done by the National Institute of Health," Dr. Kevin Ault, associate professor of gynecology and obstetrics at Emory University School of Medicine, told ABC. "You and I paid for that with our tax dollars, it's not like this pharmaceutical company is trying to recoup its investments in research and development, as is usually the reason for the price of new drugs."

The Food and Drug Administration's approval to grant KV exclusive rights to the product prevents the pharmacies that had been producing the shot from doing so anymore. It also prevents doctors from using anything but the KV formulation.

With approximately 16% of votes, Gilbert Gottfried's tasteless tweets making light of the devastation in Japan was voted the second dumbest thing on Wall Street this week.

Gottfried took to Twitter on Monday to make some inappropriate jokes about the tragedy in Japan. He was quickly fired as the voice of the Aflac (AFL - Get Report) duck.

Aflac quickly cut ties with the comedian following a string of similar comments.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AFL $62.71 -0.29%
CBS $61.59 -0.36%
COF $85.02 -0.11%
DTV $91.57 -0.63%
HPQ $34.76 2.75%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs